HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dipropylene glycol, cinnamaldehyde

This article was originally published in The Rose Sheet

Executive Summary

Draft technical reports on National Toxicology Program rodent toxicology and carcinogenesis studies on ingredients to be reviewed by NTP Board of Scientific Counselors subcommittee at a Sept. 5-6 meeting in Research Triangle Park, N.C. Dipropylene glycol is used in cosmetics, air fresheners, household cleaners and antifreeze, and cinnamaldehyde is a flavoring and fragrance ingredient. Reports to be publicly available approximately five weeks prior to meeting...

You may also be interested in...



Cinnamaldehyde Shows “No Evidence” Of Carcinogenicity In NTP Studies

Flavor and fragrance ingredient cinnamaldehyde showed "no evidence" of carcinogenic activity in rodent studies conducted by the National Toxicology Program, according to a recently-released draft report of findings

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel